NCX 470

Phase 2Small molecule

NNicox Ophthalmics, Inc.

NCX 470 is one of 38 small molecule programs targeting Ocular Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

BlepharitisActive, not recruiting

Ocular HypertensionPhase 2

Active, not recruiting

BlepharitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 2

Alphagan

Novartis

Phase 3

1 3

Comparator: Pbo

Merck & Co.

Phase 3

2 4

Azopt

Novartis

Phase 3

1 5

Ocupress

AbbVie

Phase 3

1 6

LUMIGAN

AbbVie

Phase 3

2 7

Krytantek

AbbVie

Phase 3

2 8

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 9

PRO-122

LLaboratorios Sophia S.A de C.V.

Phase 3

1 10

Duotrav

AAlcon Research

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ocular Hypertension3 trials

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed·NNicox Ophthalmics, Inc.·Phase 3·NCT04630808·696 enrolled

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed·NNicox Ophthalmics, Inc.·Phase 3·NCT04445519·691 enrolled

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed·NNicox Ophthalmics, Inc.·Phase 2·NCT03657797·656 enrolled

Blepharitis1 trial

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

Completed·NNicox Ophthalmics, Inc.·Phase 2·NCT04675242·224 enrolled

Unspecified1 trial

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

Completed·NNicox Ophthalmics, Inc.·Phase 2/3·NCT05938699·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for NCX 470. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NCX 470 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NCX 470. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nicox Ophthalmics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNicox Ophthalmics, Inc.

NCX 470

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ocular Hypertension3 trials

Blepharitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News